Indiana University Health implements new operating model, consolidating regions and eliminating nonclinical leadership roles to improve patient care.

Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 ...

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

During the conference, Mr. Sapirstein will be available to conduct one-on-one meetings with registered investors, showcasing ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the ...

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal ...

Daré will host a conference call and live webcast today, November 14, 2024, at 4:30 p.m. Eastern Time to review financial ...

Jaguar Health announced that its product, cofelemer delayed-release tablets (Canalevia-CA1; Jaguar Health), received approved ...

Norton West Louisville Hospital opened its doors to patients Monday, Nov. 11, giving residents of West Louisville access to ...